Skip to main content

NUCLEAR EXCLUSION OF P53 CONTROLS DNA-SYNTHESIS THROUGH REDUCTION IN THE EXPRESSION OF P21 INHIBITOR OF CYCLIN-DEPENDENT KINASE-2

Buy Article:

$42.00 + tax (Refund Policy)

Changes in the expression of the putative p53-inducible inhibitor p21 of cyclin-dependent kinase (CDK) and p21-associated CDK activity were examined in relation to the DNA synthesis-associated nuclear exclusion of p53 after stimulating growth arrested human breast cancer MCF7 cells with serum. Following stimulation, p53 was coincidentally excluded from the nucleus to the cytoplasm with a major increase in DNA synthesis that occurred 24 h later. The p53 protein in the cytoplasm formed a complex with a 44-kDa protein (p44). Northern blots and reverse transcription-polymerase chain reaction (PCR) revealed that the mRNA levels of p21 were unchanged immediately before and after stimulation, but were reduced significantly 24 h later. Immunoprecipitation showed that newly synthesized p21 coprecipitated with CDK2 but not with CDK4. Synthesis of p21, the level of which was high in arrested cells, decreased after stimulation and remained at low levels thereafter. The CDK2 activity as assessed by histone H1 kinase activity in vitro was low in arrested cells and changed in parallel with DNA synthesis after stimulation. The present results suggest that the nuclear exclusion and complex formation of p53 with p44 in the cytoplasm control DNA synthesis by reducing p21 expression, thereby leading to the activation of CDK2.

Document Type: Research Article

Publication date: 01 November 1994

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content